Introduction to "A Road Map for Intravenous Iron and Anemia Management: Preparing for the Future"

American Journal of Kidney Diseases

Volumn 52, Issue 6 SUPPL. 1, 2008, Pages

  Coyne, Daniel W ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ERYTHROPOIETIN; HEMOGLOBIN; IRON; RECOMBINANT ERYTHROPOIETIN;

ANEMIA; CHRONIC KIDNEY DISEASE; CLINICAL TRIAL; DRUG EFFECT; DRUG EFFICACY; DRUG INDICATION; DRUG USE; ERYTHROCYTE TRANSFUSION; HEMATOCRIT; HUMAN; REVIEW; TREATMENT OUTCOME;

ANEMIA; DRUG THERAPY, COMBINATION; HEMATINICS; HEMOGLOBINS; HUMANS; INJECTIONS, INTRAVENOUS; IRON; KIDNEY FAILURE, CHRONIC; RENAL DIALYSIS;

EID: 55749106037     PISSN: 02726386     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.ajkd.2008.09.002     Document Type: Review

References (28)

1. Deicher R., Zial F., Cohen G., Müllner M., and Hörl W. High-dose parenteral iron sucrose depresses neutrophil intracellular killing capacity. Kidney Int 64 (2003) 728-736
2. National Kidney Foundation. KDOQI Clinical Practice Guidelines and Clinical Practice Recommendations for Anemia in Chronic Kidney Disease. Am J Kidney Dis 47 suppl 3 (2006) S11-S145
3. US Renal Data System. USRDS 1996 Annual Data Report (1996), The National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, MD
4. National Kidney Foundation. NKF-DOQI Clinical Practice Guidelines for the Treatment of Anemia of Chronic Renal Failure. Am J Kidney Dis 30 suppl 3 (1997) S192-S240
5. Centers for Medicare & Medicaid Services. 2006 Annual Report, End-Stage Renal Disease Clinical Performance Measures Project (2007), Department of Health and Human Services, Centers for Medicare & Medicaid Services, Office of Clinical Standards and Quality, Bethesda, MD
6. Centers for Medicare & Medicaid Services. 2005 Annual Report, End-Stage Renal Disease Clinical Performance Measures Project (2005), Department of Health and Human Services, Centers for Medicare & Medicaid Services, Office of Clinical Standards and Quality, Baltimore, MD
7. US Renal Data System. USRDS 2007 Annual Data Report (2007), The National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, MD
8. Drüeke T.B., Locatelli F., Clyne N., et al., CREATE Investigators. Normalization of hemoglobin level in patients with chronic kidney disease and anemia. N Engl J Med 355 (2006) 2071-2084
9. Singh A.K., Szczech L., Tang K.L., et al., CHOIR Investigators. Correction of anemia with epoetin alfa in chronic kidney disease. N Engl J Med 355 (2006) 2085-2098
10. Besarab A., Bolton W.K., Browne J.K., et al. The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin. N Engl J Med 339 (1998) 584-590
11. Leavitt M.O. Secretary of Health and Human Services. Report to Congress: A Design for a Bundled End-Stage Renal Disease Prospective Payment System, 2008. http://www.cms.hhs.gov/ESRDGeneralInformation/Downloads/ESRDReportToCongress.pdf Accessed April 24, 2008
12. Thamer M., Zhang Y., Kaufman J., Cotter D., Dong F., and Hernán M.A. Dialysis facility ownership and epoetin dosing in patients receiving hemodialysis. JAMA 297 (2007) 1667-1674
13. Wish J.B. The economic realities of erythropoiesis-stimulating agent therapy in kidney disease. Kidney Int Suppl 70 (2006) S21-S25
14. Singh A.K. The controversy surrounding hemoglobin and erythropoiesis-stimulating agents: What should we do now?. Am J Kidney Dis 52 suppl 1 (2008) S5-S13
15. US Food and Drug Administration and Center for Drug Evaluation and Research. Information for Healthcare Professionals: Erythropoiesis Stimulating Agents (ESA). http://www.fda.gov/cder/drug/InfoSheets/HCP/RHE2007HCP.htm Accessed February 25, 2008
16. Centers for Medicare & Medicaid Services. CMS Manual System. Pub 100-04 Medicare Claims Processing. Transmittal 1307. Change Request 5700. 7-20-2007. http://www.cms.hhs.gov/Transmittals/Downloads/R1307CP.pdf Accessed January 3, 2008
17. Coyne D.W. A comprehensive vision for intravenous iron therapy. Am J Kidney Dis 52 suppl 1 (2008) S14-S20
18. Coyne D.W., Kapoian T., Suki W., et al., DRIVE Study Group. Ferric gluconate is highly efficacious in anemic hemodialysis patients with high serum ferritin and low transferrin saturation: Results of the Dialysis Patients' Response to IV Iron with Elevated Ferritin (DRIVE) Study. J Am Soc Nephrol 18 (2007) 975-984
19. Singh A.K., Coyne D.W., Shapiro W., Rizkala A.R., and DRIVE Study Group. Predictors of the response to treatment in anemic hemodialysis patients with high serum ferritin and low transferrin saturation. Kidney Int 71 (2007) 1163-1171
20. Gotloib L., Silverberg D., Fudin R., and Shostak A. Iron deficiency is a common cause of anemia in chronic kidney disease and can often be corrected with intravenous iron. J Nephrol 19 (2006) 161-167
21. Sunder-Plassmann G., and Hörl W.H. Erythropoietin and iron. Clin Nephrol 47 (1997) 141-157
22. Kapoian T. Challenge of effectively using erythropoiesis-stimulating agents and itravenous iron. Am J Kidney Dis 52 suppl 1 (2008) S21-S28
23. Kapoian T., O'Mara N.B., Singh A.K., et al. Ferric gluconate reduces epoetin requirements in hemodialysis patients with elevated ferritin. J Am Soc Nephrol 19 (2008) 372-379
24. Pizzi L.T. Economic considerations in a changing anemia environment. Am J Kidney Dis 52 suppl 1 (2008) S29-S33
25. National Kidney Foundation. KDOQI Clinical Practice Guideline and Clinical Practice Recommendations for Anemia in Chronic Kidney Disease, 2007 Update of Hemoglobin Target. Am J Kidney Dis 50 (2007) 471-530
26. Fishbane S., and Berns J.S. Hemoglobin cycling in hemodialysis patients treated with recombinant human erythropoietin. Kidney Int 68 (2005) 1337-1343
27. Besarab A. Resolving the paradigm crisis in intravenous iron and erythropoietin management. Kidney Int Suppl 69 (2006) S13-S18
28. Ebben J.P., Gilbertson D.T., Foley R.N., and Collins A.J. Hemoglobin level variability: Associations with comorbidity, intercurrent events, and hospitalizations. Clin J Am Soc Nephrol 1 (2006) 1205-1210